PrepQuant System Integrates Key Workflow Steps
Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, has introduced the PrepQuant System. This advanced sample preparation platform aims to standardise and streamline pre-analytical workflows in molecular testing.
Developed in collaboration with Hitachi High-Tech Corporation, the system integrates nucleic acid extraction, concentration, and quantification into a single automated instrument. Invivoscribe’s expertise in developing standardised molecular assays, combined with Hitachi High-Tech’s technological capabilities, has resulted in this innovative solution.
The PrepQuant System is designed to reduce costs and variability in testing processes. It is assay agnostic, producing highly concentrated genomic DNA and cell-free DNA (cfDNA) yields suitable for next-generation sequencing (NGS), qPCR, and digital PCR (dPCR) assays.
Jeff Miller, CEO and CSO of Invivoscribe, highlighted the significance of the system. He stated, “By integrating extraction, concentration, and quantification in one platform, we reduce variability to help ensure generation of consistent, high-quality test results.” This is crucial in the era of precision medicine, where the reliability of MRD and liquid biopsy results depends on the quality of the starting material.
Advanced Capabilities and Global Rollout
The PrepQuant System consolidates multiple steps in a single platform, significantly reducing laboratory operating costs, sample variability, and lab bench space, while optimizing test results. This efficiency is expected to transform laboratory operations.
Jordan Thornes, VP of Global Clinical Laboratory Operations at Invivoscribe, commented on the system’s potential to improve operational efficiency. He said, “Our teams recognised the limitations of currently available automated instruments, particularly the labor-intensive nature and increased risk of errors associated with running three separate protocols across multiple instruments.”
The system is validated for use with blood, plasma, and bone marrow specimens, with ongoing development for additional specimen types. Invivoscribe plans to unveil the system at the American Association for Cancer Research (AACR) Annual Meeting in San Diego from April 19 to 22.
Commercial shipments in North America are expected to start in August 2026, with European availability projected for January 2027. New kit releases are anticipated by the end of 2026 to expand the system’s versatility. The company is also issuing quotes to potential customers and actively engaging with stakeholders to ensure a smooth rollout.
Importantly, the collaboration with Hitachi High-Tech has leveraged their extensive global installed base of life science and clinical diagnostic instruments, ensuring that the PrepQuant System benefits from robust technological and manufacturing capabilities. This partnership underscores Invivoscribe’s commitment to innovation and efficiency in molecular testing.
Last updated: 15 April 2026, 9:49 pm
